Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma.

ABSTRACT:

Background

Lung cancer is the leading cause of cancer-related mortality worldwide. Low-dose CT (LDCT) imaging is now recommended to screen high-risk lung cancer individuals in the USA. LDCT has resulted in increased detection of stage I lung cancer for which the current standard of care is surgery alone. However, approximately 30% of these patients develop recurrence and therefore are in need of further treatment upon diagnosis. This study aims to explore blood-based inflammatory biomarkers to identify patients at high-risk of mortality for which additional treatment modalities can be offered at time of diagnosis.

Patients and methods

Recent work on a small panel of circulating cytokines identified elevated levels of IL-6, a pro-inflammatory cytokine, as an indicator of poor

SUBMITTER: Meaney CL 

PROVIDER: S-EPMC5522266 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature